Changing the Face of Cancer – Chris O'Brien Lifehouse
 In Lifehouse News

Every year Cancer Institute NSW tracks and analyses data on cancer outcomes from public and private hospitals across the state. The report provides an up-to-date snapshot of performance  that includes not only treatment but also prevention, screening and clinical trials.

We are proud to share our results. In the six short years that we have been open for surgery, we have become the largest surgical centre for head and neck and breast cancer and the third largest for ovarian cancer.

There is no doubt that evidence shows that treatment at high surgical volume centres leads to better outcomes. Patients treated at Chris O’Brien Lifehouse have a much higher chance of surviving ovarian, head and neck, lung and neurological cancer, and sarcoma than the NSW average.

How we performed in 2020

The key findings of the report are:

  • In all but two cancer types (gastric and bladder), the our caseload significantly exceeds the minimum suggested hospital caseload. Evidence shows a link between higher caseload and better outcomes like post-operative mortality and five-year survival rates.
  • Having surgery in a higher-volume centre is particularly important for complex procedures.
  • Five-year relative survival for all people diagnosed with cancer has increased by as much as 28% for some age groups and by an average of 17% for all age groups, since 1981.
  • All cancer cases at Chris O’Brien Lifehouse are reviewed by an on site multidisciplinary team, except for liver cancer and melanoma which are reviewed on campus at Royal Prince Alfred Hospital and the Melanoma Institute of Australia.

Patients treated here have a better chance of survival at one year than the NSW average for:

  • Head and neck cancer
  • Ovarian cancer
  • Colon cancer
  • Lung cancer
  • Neurological cancer
  • Oesophageal cancer
  • Breast cancer

Patients reported high levels of satisfaction with their experience at our outpatient cancer clinics for:

  • Worries or fears completely discussed by health professionals
  • Completely given enough information to manage side effects
  • Not needing to attend emergency department during treatment or due to complications
  • Informed of contact if worried after leaving clinic
  • Care received at clinic was very well organised
  • Asked about care and treatment when developing the care plan
  • Very good rating of health professionals and of care received
  • Always treated with respect and dignity
  • Had confidence and trust in the health professionals.

We opened 85 new cancer clinical trials in 2019-2020.

Surgical outcomes

When compared to the NSW average, our patients have a higher chance of surviving many types of cancer.

Head and neck cancer

  • 53% lower 30-day mortality
  • 25% lower 1-year mortality

Oesophageal cancer

  • 84% lower 30-day mortality

Soft tissue sarcoma

  • 50% lower 90-day mortality

Ovarian cancer

  • 34% lower 1-year mortality

Neurological cancer

  • 50% lower 30-day mortality
  • 79% lower 90-day mortality
  • 63% lower 1-year mortality

Lung cancer

  • 47% lower 30-day mortality
  • 58% lower 90-day mortality
  • 49% lower 1-year mortality
Recent Posts

Start typing and press Enter to search